Last reviewed · How we verify
NPC-02
NPC-02 is a small molecule that targets the SGLT2 receptor.
NPC-02 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | NPC-02 |
|---|---|
| Sponsor | Nobelpharma |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
By inhibiting SGLT2, NPC-02 reduces glucose reabsorption in the kidneys, lowering blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes.
Approved indications
- Type 2 diabetes
Common side effects
- Increased risk of genital yeast infections
Key clinical trials
- Efficacy and Safety, Long-term Study of Zinc Acetate to Treat Wilson's Disease in Japan. (PHASE3)
- A Randomized, Double-Blind, Placebo Controlled Study of NPC-02 in Patients With Zinc Deficiency (PHASE3)
- Dose Adjustment Study of NPC-02 in Patients With Zinc Deficiency (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NPC-02 CI brief — competitive landscape report
- NPC-02 updates RSS · CI watch RSS
- Nobelpharma portfolio CI